When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.
When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.
Transcript (slightly modified)
What are some important considerations in designing health interventions for minority populations?
The 2 parts are, first of all, the attitude. I believe our attitude determines our altitude, how far we can go and how high we can go. It’s the recognition that all racial/ethnic minorities are different, all populations are different, and the first attitude must be that of humility, of really trying to understand the cultural aspects, the behavioral aspects, the determinants of population health.
Secondly, it’s some sort of ascertainment: compiling and knowing the epidemiology, the risk factors, the rates, which cancers and risk factors are the most prominent and what can be done about it. Then, to the extent possible, to design interventions that are culturally competent, meaning with the population, not on the population. That might mean training bilingual, bicultural individuals who can reach out to the community.
I think that conducting this, sustaining that, is the way to go. We’ve been able to show that it has worked. It’s more effective than, shall we say, just a missile approach or whatever.
What role can clinicians play in improving population health?
I want to reinforce how important, and never to underestimate, the provider’s influence on healthcare of the patient. The provider is the major gateway, decision maker, and trusted individual to do this, and so that’s a tremendous responsibility and obligation to do. I feel really privileged whenever I can to just reflect the research and the patient community on how important the provider’s role is.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More